Anatomic Stage II Breast Cancer AJCC v8 Clinical Trials in Columbus, Ohio

10 studies are recruiting for anatomic stage ii breast cancer ajcc v8 in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

   This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   556 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06058377 on ClinicalTrials.gov

2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

   This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   183 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07391774 on ClinicalTrials.gov

3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

   This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemothera…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   690 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06876714 on ClinicalTrials.gov

4. A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

   This clinical trial studies whether a navigation program improves survivorship support service participation among survivors of breast cancer that has not spread from where it first started (primary site) to other places in the body (non-metastatic). Advances in treatment have caused the number of …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT07699991 on ClinicalTrials.gov

5. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

   This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemot…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   846 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05812807 on ClinicalTrials.gov

6. Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

   This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). The stress reduction program is over ten weeks and includes stress reduction …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   2 in total

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT05677802 on ClinicalTrials.gov

7. Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

   This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced q…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT05417308 on ClinicalTrials.gov

8. The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

   This study is being done to learn more about breast cancer patients' experiences with sleep changes during cancer treatment, identify possible reasons for poor sleep quality, and to find out how stress, social support, and living environment affect sleep.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT07341503 on ClinicalTrials.gov

9. Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

   The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced by women with newly diagnosed stage II-III triple negative breast canc…

   Stage

   Not phased

   Ages

   40 to 65

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   2 in total

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT06582615 on ClinicalTrials.gov

10. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Locations

    963 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT05929768 on ClinicalTrials.gov